Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

UKR, Israel aid bill blocked
Accuses Allen of being rude
Slams body shamer on-air
To be released in Japan
‘The Rose Tattoo' star dies
Stress led to Bell’s palsy
‘Enough is enough’
52 sea turtles w/ 'cold stun'
British poet, activist dies
Recreational pot legal in Ohio
To receive Serbian passport
Teen faces murder charges
Jackson, Nyong'o dating?
Capitol riot conviction
Saints claim Monty Rice
New sanctions in Mexico
Set to face a censure vote
Peru's ex-president released
McKinsey cuts partner class
Russia sets election date
Fake aircraft parts scandal
30-day visa-free travel pact
Withdrawing from S. Korea
UNLV-Dayton game canceled
To buy Cerevel for $8.7B
Oilers beat Hurricanes
Listeria contamination recall?
EU, Chinese leaders meet
AI powered image generator
Suing Hauser over coffee
Reality show winner revealed
China's exports grow
In merger talks w/ Santos
Zach LaVine injury update
3-yr extension w/ Dolphins
Dončić makes NBA history
FR to ramp up hotel checks
‘I loved him dearly’
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
5,170 results
Proactiveinvestors28d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
The Motley Fool20d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
Reuters23d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN28d
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
The Financial Times28d
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...
Morningstar3d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
MarketWatch28d
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Investing17d
AstraZeneca: Leading bank tells us why the stock is a core holding
Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...
Proactive Investors28d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices